本公司的电邮信箱于今日起已由 "info@newbinnovation.com" 变更为 "info@newbetainnovation.com"。

本公司的英文名称已由 "New B Innovation Limited" 变更为 "New Beta Innovation Limited"，自2019 年6 月3 日起生效。此外，公司的中文名称 "新行健医药科技有限公司" 则维持不变。

请知悉是次命名变更是不会影响公司架构以及本公司对外已签署的合同及协议书。

The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.

New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.